Search - tctmd.com

$Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial$

Presentation EuroPCR 2014

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

Presenter: Uwe Zeymer

May 21, 2014

News Conference News EuroPCR 2014

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

Yael L. Maxwell

May 21, 2014

Presentation

Prasugrel plus Bivalirudin vs Clopidogrel plus Heparin in Patients with STEMI

Presenter: Stefanie Schulz

May 14, 2014

News Daily News

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

May 14, 2014

News Daily News

Hospital-Acquired Thrombocytopenia Increases Risk of Hospital Bleeding, 1-Year Mortality

May 05, 2014

News Daily News

Bivalirudin Safer Than Heparin Alone in ‘Real-World’ PCI Patients Without STEMI

Yael L. Maxwell

May 01, 2014

Presentation

Heparin Monotherapy or Bivalirudin During PCI in NSTE-ACS or Stable Ischemic Heart Disease

Presenter: Sripal Bangalore

April 22, 2014

News Daily News

STEMI Patients with Large Thrombus Benefit from Low-dose Thrombolysis

Yael L. Maxwell

April 10, 2014

Advertisement

HEAT-PPCI Publicado: El Discrepante Hallazgo de la Superioridad de la Heparina sobre la Bivalirudina en PCI Primarias Sigue Confundiendo

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

La Mortalidad a Largo Plazo es Peor en Pacientes NSTEMI de Raza Negra que en Pacientes de Raza Blanca con Discrepancias en el Tratamiento

Unfractionated Heparin vs Bivalirudin in Primary PCI: An Open-label, Single-Center, Randomized Trial

ACUITY分项研究： Syntax评分与NSTE-ACS患者的支架内血栓形成有关联

ACUITY Substudy: Syntax Score Correlates with Stent Thrombosis in NSTE-ACS Patients

Subestudio ACUITY: La Puntuación obtenida en la Escala Syntax Guarda Relación con la Trombosis del Stent en Pacientes SCASEST

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

Strategy of Potent Anticoagulation with Rapid Post-PCI Reversal Appears Safe, Effective

Una Estrategia de Anticoagulación Potente con Reversión Rápida Post-PCI parece Segura y Efectiva

Prasugrel Efficacy in STEMI Largely Unaffected by PCI Timing

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

Prasugrel plus Bivalirudin vs Clopidogrel plus Heparin in Patients with STEMI

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

Hospital-Acquired Thrombocytopenia Increases Risk of Hospital Bleeding, 1-Year Mortality

Bivalirudin Safer Than Heparin Alone in ‘Real-World’ PCI Patients Without STEMI

Heparin Monotherapy or Bivalirudin During PCI in NSTE-ACS or Stable Ischemic Heart Disease

STEMI Patients with Large Thrombus Benefit from Low-dose Thrombolysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content